IMUX - NASDAQ
Immunic, Inc.
$14.43
+0.63%Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
At a Glance
Live SnapshotImmunic, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Immunic, Inc. Cash Flow Statement
IMUX • NASDAQ
| Immunic, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||||
-97.2M | -100.5M | -93.6M | -120.4M | -92.9M | -44M | -34.9M | -41.5M | -52.1M | -41M | -52M | -47.7M | -32.7M | -6.7M | -5.9M | |
168K | 134K | 111K | 77K | 85K | 39K | 50K | 727K | 998K | 1.8M | 1.3M | 1.1M | 799K | 651K | 961K | |
0.0 | 0.0 | 0.0 | 0.0 | 4.3M | 0.0 | -355K | 1.2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -7K | 0.0 | |
8.9M | 8.5M | 7.1M | 7.9M | 5.9M | 2.7M | 6.5M | 3.7M | 5.5M | 4.7M | 4M | 2.5M | 948K | 144K | 36K | |
497K | 6.5M | 523K | 37.7M | 8.6M | -2.5M | 1.5M | 234K | 255K | 85K | 6.7M | -2.6M | 1.3M | -2.9M | -2.8M | |
1.8M | 564K | 15M | 9.5M | -9.3M | -2.4M | -1.4M | -7.6M | 4.9M | -1.4M | -3.3M | 5.8M | 1M | -473K | -104K | |
-85.8M | -84.8M | -70.8M | -65.1M | -83.2M | -46.1M | -28.5M | -43.2M | -40.4M | -35.8M | -50M | -40.8M | -28.6M | -9.2M | -7.8M | |
INVESTING ACTIVITIES | |||||||||||||||
-161K | -264K | -334K | -112K | -67K | -146K | -55K | -597K | -685K | -556K | -2.3M | -1.4M | -1.5M | -261K | -18K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (10.7M) | (0.0) | (7K) | (2K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | -9.6M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -3M | -14M | (0.0) | |
0.0 | 0.0 | 9.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 17M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -75K | 182K | 7K | 535K | 1.1M | -631K | -608K | -335K | 0.0 | |
-161K | -264K | (9.5M) | -9.7M | -67K | -146K | (10.5M) | -415K | -678K | -21K | -1.3M | -2M | (11.9M) | -14.6M | -18K | |
FINANCING ACTIVITIES | |||||||||||||||
65.6M | 191K | 853K | 39.6M | 42.7M | 144.4M | 35.2M | 0.0 | 38M | 12.4M | 32.2M | 87.9M | 0.0 | 0.0 | 0.0 | |
0.0 | 74.3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.4M | 2.3M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -4.7M | (0.0) | (0.0) | (0.0) | |
0.0 | 77K | 180K | 187K | 92K | 0.0 | -270K | 4K | -14K | 19K | 232K | 5.6M | -2.8M | 0.0 | -32K | |
65.6M | 74.5M | 1M | 95.8M | 42.8M | 144.4M | 34.9M | 4K | 38M | 12.4M | 32.4M | 106.9M | 50.4M | 27.5M | 8.3M | |
CASH FLOW SUMMARY | |||||||||||||||
205K | -517K | 262K | -993K | -130K | -78K | -589K | -1K | 1K | -4K | -10K | -1K | 3K | 5K | 12K | |
-20.2M | -11M | -60.1M | 19.9M | -40.6M | 98.1M | 16.3M | -43.6M | -3.1M | -23.4M | -18.8M | 64.1M | 33.7M | 3.7M | 416K | |
35.7M | 46.7M | 106.7M | 86.9M | 127.5M | 29.4M | 13.1M | 56.9M | 60M | 83.4M | 102.2M | 38.2M | 4.5M | 803K | 387K | |
15.5M | 35.7M | 46.7M | 106.7M | 86.9M | 127.5M | 29.4M | 13.3M | 56.9M | 60M | 83.4M | 102.2M | 38.2M | 4.5M | 803K | |
-86M | -85M | -71.2M | -65.3M | -83.3M | -46.3M | -28.6M | -43.8M | -41.1M | -36.3M | -52.3M | -42.2M | -30.1M | -9.5M | -7.8M |
SEC Filings
IMUX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | May 29, 2026 | June 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 28, 2026 | May 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 27, 2026 | May 22, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 19, 2026 | May 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
S-3/A S-3/A (Amended) N/A | April 30, 2026 | April 30, 2026 | ||
8-K 8-K 2026 N/A | April 28, 2026 | April 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 23, 2026 | April 22, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 22, 2026 | December 31, 2025 | 2025 |
Related Guides
Continue your IMUX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.